Asset Details
Do you wish to reserve the book?
Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours
Do you wish to request the book?
Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours
2025
Overview
Purpose
microRNA-371a-3p (M371) is considered a highly sensitive and specific serum biomarker of testicular germ cell tumours (GCTs). However, little is known about the expression of M371 in nontesticular malignancies (NTMs), so far. As knowledge about the expression of the marker in other malignancies is a prerequisite for the clinical application of the test we aimed to explore the M371 expression in other cancers.
Methods
M371 serum levels were measured in 137 patients with NTM of 12 different neoplastic entities using the IVDR-certified M371-Test for quantitative real-time PCR. Median M371 serum levels and percentages of M371 level elevations were calculated for the entire NTM group and for entity-specific subgroups. The results were compared with GCT patients (
n
= 20) and with tumour-free male controls (
n
= 20) using descriptive statistical methods.
Results
Eight patients with NTMs had M371 serum level elevations, corresponding to a false-positive rate (FPR) of 5.84% (95% confidence intervals (CIs) 2.55–11.18%). Expression rates in GCTs and controls were 100% and zero, respectively. Thus, the specificity of the M371-Test for GCT is 94.90% (95% CI 90.21–97.77%) when all NTMs and tumour-free controls are considered. Remarkably, three out of 5 patients with multiple myeloma had elevated M371 levels.
Conclusion
The false-positive rate of the M371-Test in other malignancies than GCT is very low, and almost identical with that in healthy males, corresponding to a high specificity of 94.9% for detection of GCT. The surprising finding of M371 elevations in patients with multiple myeloma needs further investigation.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V,Springer
Subject
/ Adult
/ Aged
/ Biomarkers, Tumor - genetics
/ Chromosome 19, test specificity
/ Female
/ Humans
/ Male
/ males
/ Medicine
/ miRNA
/ myeloma
/ Neoplasms, Germ Cell and Embryonal - blood
/ Neoplasms, Germ Cell and Embryonal - genetics
/ Oncology
/ quantitative polymerase chain reaction
/ testes
/ Testicular Neoplasms - blood
/ Testicular Neoplasms - genetics
/ Tumors
